***Staphylococcus aureus* Resistance Patterns in Wisconsin: 2018 Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) Program Report**

Rebecca H. Schulte, BS and Erik Munson, PhD

Objective: Surveillance of antimicrobial resistance patterns on a local level can reveal paradigms not obvious on a regional or national scale. Data collection from this perspective may potentially impact local prescribing patterns and empiric treatment guidelines. The objective of this study was to establish a baseline *Staphylococcus aureus* antibiogram for the state of Wisconsin and to elucidate potential geographic and demographic factors associated with antimicrobial resistance.

Design: Multi-center laboratory surveillance, with testing at a single site utilizing standardized media and susceptibility testing protocols.

Methods: 309 isolates of clinically-significant *S. aureus* were collected from hospital microbiology laboratories across Wisconsin in 2018, with distribution across seven geographic regions. Each isolate was tested using reference broth microdilution methods against a panel of 15 antimicrobial agents. Percentage susceptibility data, as well as median and 90th percentile minimum inhibitory concentration (MIC) values, were computed for each antimicrobial agent as a function of geographic region or demographic category.

Results: Increased resistance to penicillin ($\geq 86.0\%$ of isolates), erythromycin ($\geq 56.8\%$), cefoxitin ($\geq 45.5\%$), levofloxacin ($\geq 25.0\%$), and clindamycin ($\geq 20.5\%$) was observed in the Southcentral, Lake Winnebago, and Southeast regions of Wisconsin. In addition, isolates phenotypically classified as methicillin-resistant *S. aureus* (MRSA) were found to have increased rates of resistance to clindamycin, erythromycin, and levofloxacin as compared to *S. aureus* isolates susceptible to cefoxitin. *S. aureus* isolates demonstrated nearly 100% in vitro susceptibility to ceftaroline, dalbavancin, and telavancin. Statewide *S. aureus* isolates exhibited a vancomycin MIC₉₀ of 1 $\mu\text{g/mL}$. *S. aureus* isolates from patients aged 20-39 years were more likely to demonstrate cefoxitin resistance when compared to other age groups ($P \leq 0.03$), while isolates from patients ≥ 80 years were more likely to exhibit resistance to levofloxacin and clindamycin ($P \leq 0.046$).

Conclusions: Several antimicrobial agents continue to demonstrate in vitro efficacy against clinical isolates of *S. aureus* (including MRSA) throughout Wisconsin, including three agents with recently-published susceptibility testing guidelines. However, continued surveillance efforts may be necessary in the Lake Winnebago, Southeast, and Southcentral regions to further assess higher rates of resistance to a number of antimicrobial agents.

Keywords: *Staphylococcus aureus*; Antimicrobial resistance; Surveillance

Corresponding Author: Erik Munson, PhD, Department of Clinical Laboratory Science, Marquette University, PO Box 1881, Milwaukee, Wisconsin 53201-1881
Telephone: (414) 288-5848, Fax: (414) 288-7948, Email: erik.munson@marquette.edu

Received: May 2, 2019
Revised: July 18, 2019
Accepted: August 7, 2019

doi:10.3121/cmr.2019.1503

Financial Support: The research received support from the Wisconsin Department of Health Services, Division of Public Health (ELC Project K2: HAI Coordinated Prevention and Stewardship).

According to the World Health Organization, significant increases in antimicrobial resistance have occurred in recent years.¹ In addition to agents of healthcare-associated infection such as extended-spectrum β -lactamase-producing *Enterobacteriales*, carbapenemase-producing organisms, and vancomycin-resistant enterococci,^{2,4} emerging agents such as *Candida auris*⁵ and antibiotic-resistant *Neisseria gonorrhoeae*⁶ are impacting clinical management of patients and economics of healthcare.⁷ This has resulted in a need for novel antimicrobial agents and new means of treatment for disease states involving these resistant strains.⁸ However, antimicrobial research and development efforts may not come to fruition due to cost considerations or discovery of unexpected toxicity profiles. As a result, development efforts have largely turned to antimicrobial compounds already in use, with the possibility of using them in new combinations (often paired with β -lactamase inhibitor compounds) to enhance their efficacy. Due to the paucity of novel antimicrobial agents, antimicrobial resistance surveillance can be a means of assessing agents that are currently utilized.⁹ It is important to study these strains of increasingly-resistant bacteria due to potentially novel resistance mechanisms and the potential of developing resistance to alternative therapeutic options.¹⁰

Staphylococcus aureus is a common human pathogen, with increased antimicrobial resistance complicating therapeutic

measures in recent years. In 2014, portions of Southeast Asia, the Western Pacific, and other regions of the world reported greater than 80% of *S. aureus* infections having a methicillin-resistant *S. aureus* (MRSA) phenotype.¹¹ In the United States, MRSA was deemed a serious antibiotic resistance threat by the Centers for Disease Control and Prevention in a 2013 report.¹² Studies have demonstrated that MRSA isolation rates have declined in recent years, yet additional adjunctive surveillance and prevention may be necessary to further decrease the spread of this pathogen. Between 2005-2008, Diekema, et al¹³ documented international MRSA rates of 44.2%. By 2016, this rate declined to 39.0%. A study by Sader, et al¹⁴ reported a shift in MRSA rates from 50.0% to 42.2% between 2010 and 2016 in United States hospitals. Landrum, et al¹⁵ reported decreased trending between 2005 and 2010 for community-onset MRSA bacteremia, hospital-onset MRSA bacteremia, and community-onset skin and soft tissue infection due to MRSA among United States military personnel. By monitoring antibiotic resistance on a local level, healthcare professionals can make informed decisions regarding antimicrobial therapy and infection prevention.¹⁶⁻¹⁸

In 2014, the Wisconsin Clinical Laboratory Network (WCLN) undertook an effort to monitor statewide antimicrobial resistance patterns.¹⁹ This means of monitoring involved a compilation of antibiograms submitted on a voluntary basis. Two years later,^{16,17} the Surveillance of Wisconsin Organisms

Figure 1. Distribution of seven Wisconsin geographic regions defined by the SWOTARE program, 2018.

Figure 2. Distribution of Wisconsin *Staphylococcus aureus* surveillance isolates on the basis of patient age, 2018.

for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) program initiated an improved understanding of frank and emerging resistance by both determining percentage susceptibility data and calculating minimum inhibitory concentration (MIC) frequency distributions by Wisconsin region.

The purpose of this SWOTARE program investigation was to establish a Wisconsin *S. aureus* antibiogram and to elucidate potential geographic and demographic factors associated with antimicrobial resistance. Clinically-significant *S. aureus* isolates collected throughout the state were tested in a central laboratory using a standardized method. The presented antibiogram and associated ancillary data can serve as a baseline for future monitoring and surveillance of *S. aureus* antimicrobial resistance patterns throughout the state of Wisconsin.

Materials and Methods

Region Demarcation

The seven bioterrorism preparedness regions of the WCLN, as

originally defined in 2001, served as the basis for geographic comparison within this study. Population density for each region was determined by querying 2010 United States Census population data for each county within a region (Figure 1), with that sum divided by the aggregate land area of counties located in that region (<https://legis.wisconsin.gov/lrb/blue-book/>).

Study Site Recruitment

Three study sites were chosen from each region for provision of bacterial isolates. To prevent potential bias from larger population centers, two hospital microbiology laboratories from more rural areas and one from an area of higher population within the region were selected. Study locations included microbiology laboratories in Eau Claire, Spooner/Ashland, and St. Croix Falls/Amery (Northwest region); Stevens Point, Marshfield, and Weston (Northcentral region); Green Bay (two locations) and Manitowoc (Northeast region); La Crosse, Platteville/Prairie du Chien, and Viroqua (Southwest region); Madison, Janesville/Monroe, and Fort Atkinson (Southcentral region); Appleton, Neenah, and Fond

Figure 3. Distribution of Wisconsin *Staphylococcus aureus* surveillance isolates on the basis of specimen source, 2018.

■ Percentage susceptible 5% or more greater than state mean
■ Percentage susceptible $\pm 5\%$ of state mean
■ Percentage susceptible 5% or more less than state mean

Figure 4. Wisconsin geographic differences in *Staphylococcus aureus* susceptibility to (A) cefoxitin, (B) levofloxacin, (C) erythromycin, and (D) clindamycin, 2018.

du Lac (Lake Winnebago region); and, Milwaukee, West Allis, and West Bend (Southeast region).

Selection of Isolates

Study sites were requested to forward 14-15 clinically-significant isolates of *S. aureus* to a centralized testing laboratory. Isolates were collected in consecutive (non-duplicate) fashion regardless of cefoxitin susceptibility result. This instruction attempted to prevent a bias toward MRSA within the collection. Any duplicate or nonviable isolates were excluded from the study. In addition, study sites were asked to provide limited demographic information related to age, gender, specimen source of isolate, and location of healthcare encounter. Access to protected health information for the purpose of surveillance was granted by the Marquette University Institutional Review Board. Because of the lack of direct involvement in the collection of specimens and because of the utilization of de-identified isolates from routine clinical care, the SWOTARE program was not considered to be

actively engaged in human research subjects' research by the Marquette University Institutional Review Board.

Test Performance

Broth microdilution antimicrobial susceptibility testing was performed and interpreted using standards published by the Clinical and Laboratory Standards Institute (CLSI).^{20,21} Each isolate was tested against the antimicrobials listed in Table 1 in serial two-fold concentration dilutions that extended beyond CLSI breakpoints for susceptibility and resistance (when appropriate). Identification of MRSA phenotype occurred via cefoxitin susceptibility testing^{20,22} on the basis of increased induction of *mecA* activity. Isolates with a penicillin MIC of ≤ 0.12 $\mu\text{g/mL}$ were subjected to nitrocefin-based β -lactamase testing, with follow-up zone edge testing for β -lactamase-negative isolates.²⁰ Isolates demonstrating a phenotype of erythromycin resistance (or intermediate resistance) and clindamycin susceptibility were subjected to inducible clindamycin resistance testing.^{20,23,24} Cefoxitin and vancomycin

Table 1. Wisconsin *Staphylococcus aureus* antibiogram with delineation into methicillin-susceptible *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA), 2018

		Percentage Susceptible		
Antimicrobial Agent		MSSA (n=194)	MRSA (n=115)	Total (n=309)
Beta-lactams	FOX	100	0.0	62.8
	PEN	17.0	0.0	11.0
	TAR	100	99.1	99.7
Macrolide	ERY	67.0	16.5	48.2
Lincosamide	CLI	81.4	63.5	74.8
Aminoglycoside	GEN	98.5	100	99.0
Fluoroquinolone	LEV	88.7	49.6	74.1
Glyco/lipopeptides	VAN	100	100	100
	DAP	100	99.1	99.7
	TEL	100	99.1	99.7
	DAL	100	100	100
Tetracyclines	TET	93.8	93.0	93.5
	DOX	95.9	95.7	95.8
Others	LZD	100	100	100
	T/S	99.5	97.4	98.7

Abbreviations: FOX, cefoxitin; PEN, penicillin; TAR, ceftaroline; ERY, erythromycin; CLI, clindamycin; GEN, gentamicin; LEV, levofloxacin; VAN, vancomycin; DAP, daptomycin; TEL, telavancin; DAL, dalbavancin; TET, tetracycline; DOX, doxycycline; LZD, linezolid; T/S, trimethoprim-sulfamethoxazole

susceptibility testing results were determined following a full 24-hour incubation.

Data Analysis

Percentage susceptible, intermediate, and resistant values, as well as median MIC (MIC₅₀) and 90th percentile MIC (MIC₉₀) determinations were made on a statewide or geographic basis. To characterize geographic variation, the statewide mean susceptibility percentage for a given organism/antimicrobial combination established a baseline value. An interval of 5% on either side of that mean represented normal distribution. Region-specific values $\geq 5\%$ less than the state mean indicated areas with increased resistance. Region-specific values $\geq 5\%$ greater than the state mean indicated less resistance potential. The significance test of proportions determined if differences in susceptibility percentage among epidemiologic comparisons were significant. The alpha level was set at 0.05 before the investigations commenced, and all *P* values are two-tailed.

Results and Discussion

Patient Demographics, Specimen Source, and Patient Location
In 2018, 309 isolates of *S. aureus* were submitted to the surveillance program. Of this total, 155 (50.2%) were isolated from males. The highest percentage of isolates was derived

from patients between the ages of 60–79 years (35.3%; Figure 2). Other age groups contributed between 12.9% and 20.1% of isolates. Most isolates emanated from inpatient care (42.4%) or outpatient (40.1%) encounters. The mean percentage of isolates emanating from inpatient collections as a function of individual study site was $39.9 \pm 5.82\%$ (median 33.3%). Only 54 isolates (17.5%) resulted from emergency department visits. Of the 309 isolates, 72.8% came from a skin and soft tissue source (178 isolates from wounds, 26 from abscesses, 21 from tissue; Figure 3). Invasive sources comprised 19.4% of the total isolates (50 from blood, 9 from aspirates, 1 from bone), and 3.6% were derived from the lower respiratory tract (8 from sputum, 3 from semi-invasive respiratory procedures).

S. aureus Antibiogram

A *S. aureus* antibiogram for the state of Wisconsin is presented in Table 1. Across the state, gentamicin and trimethoprim-sulfamethoxazole continue to maintain potency against both MRSA and methicillin-susceptible *S. aureus* (MSSA) in vitro, with $\geq 98.7\%$ susceptibility (95% confidence interval [CI] $\geq 97.4, 100$). Tetracyclines demonstrated slightly less potency against MSSA and MRSA. Other Gram-positive agents such as vancomycin and linezolid demonstrated 100% in vitro susceptibility across Wisconsin. The vancomycin MIC₉₀ value

Table 2. MIC₅₀, MIC₉₀, and percentage susceptibility (%S) of Wisconsin *Staphylococcus aureus* isolates to doxycycline, stratified by geographic region, 2018

	Northwest	Northcentral	Northeast	Southwest	Southcentral	Lake Winnebago	Southeast	Wisconsin
n	45	43	45	45	44	44	43	309
MIC₅₀	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5
MIC₉₀	≤ 0.5	≤ 0.5	≤ 0.5	4	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5
%S	95.6	95.3	100	91.1	95.5	100	93	95.8

for Wisconsin *S. aureus* isolates was 1 µg/mL, which represented at least two 2-fold dilutions below the CLSI intermediate interpretive range of 4–8 µg/mL.²⁰

With respect to doxycycline, tetracycline, and trimethoprim-sulfamethoxazole, 0.2% to 2.1% differences in percentage susceptible values for MSSA and MRSA isolates were observed statewide. However, a distinct difference between MSSA and MRSA phenotypes was observed in terms of erythromycin, levofloxacin, and clindamycin susceptibility. Susceptibility percentages decreased by 50.5% (erythromycin), 39.1% (levofloxacin), and 17.9% (clindamycin) upon phenotypic classification as MRSA (Table 1). Similar increases in macrolide and fluoroquinolone resistance rates within a MRSA phenotype were reported from a recent ocular pathogen surveillance effort in the United States.²⁵ In clinical practice, utilization of levofloxacin for staphylococcal infections is often limited to specific entities and would be used in combination with rifampin.²⁶

Geographic Variation in Wisconsin *S. aureus* Resistance

Outside of penicillin, the only agents *S. aureus* isolates throughout Wisconsin demonstrate appreciable in vitro resistance to include clindamycin (74.8% susceptibility; CI 70.0, 79.6), levofloxacin (74.1% susceptibility; CI 69.2, 79.0), and erythromycin (48.2% susceptibility; CI 42.6, 53.8) (Table 1). The identification of clindamycin-resistant isolates was augmented by a positive inducible clindamycin resistance result in 31.4% of 118 statewide isolates eligible for testing. Of Wisconsin isolates tested, 37.2% (CI 31.8, 42.6) were phenotypically classified as MRSA, with the highest rates in the Lake Winnebago (50.0%; CI 35.2, 64.8), Southeast (46.5%; CI 31.6, 61.4), and Southcentral (45.5%; CI 30.8, 60.2) regions (Figure 4A). Remaining agents exhibited strong in vitro efficacy in the context of both MSSA and MRSA.

Emerging doxycycline resistance may be evident among *S. aureus* isolates in Southwest Wisconsin. While the percentage of isolates susceptible to this agent in this region exhibited only a 4.7% deviation from the state mean (Table 2), a distinct difference in MIC₉₀ value was observed. The Southwest region MIC₉₀ value of 4 µg/mL was at least three 2-fold dilution values higher than the state MIC₉₀ value. This is important, as a doxycycline MIC of 4 µg/mL is at the upper limit of the CLSI susceptible interpretive category.²⁰ Analysis of MIC frequency distributions (in addition to susceptibility percentages) can be helpful in predicting future trends in

resistance patterns, particularly when these MIC values still lie within a CLSI susceptible interpretive category.

Past data from the United States²⁷ introduced the incidence of doxycycline resistance in MRSA phenotypes that exhibited decreased susceptibility to oxacillin, erythromycin, and levofloxacin. Within this phenotype, which represented 31% of MRSA isolates surveyed, 4.2% of isolates were resistant to doxycycline. Jones, et al²⁸ utilized the doxycycline susceptible breakpoint of 4 µg/mL to report 96.2% and 99.2% susceptibility rates for worldwide MRSA and MSSA isolates, respectively. These values were 5% greater than corresponding tetracycline susceptibility rates. MIC frequency distribution analysis of Wisconsin data regarding another alternative *S. aureus* therapeutic agent, trimethoprim-sulfamethoxazole, did not reveal potential emerging trends of resistance (data not illustrated). Additional investigation into this doxycycline/*S. aureus* paradigm from the Southwest region may be warranted to further elucidate this potential emerging resistance profile.

In addition to an increased frequency of MRSA, *S. aureus* isolates derived from the Southeast, Southcentral, and Lake Winnebago regions exhibited increased resistance to levofloxacin (Figure 4B), erythromycin (Figure 4C), and clindamycin (Figure 4D) when compared to other Wisconsin regions. In these regions, increased surveillance efforts through the SWOTARE program and concomitant adjustments to antimicrobial stewardship programs have the potential to impact future resistance profiles. Investigations are in progress to assess provider prescribing patterns within these regions of Wisconsin and to determine any correlation with known resistance patterns.

Hicks, et al²⁹ reported significant antibiotic prescription burden within outpatient settings in the United States, with over 260 million courses being prescribed by clinicians in 2011. Agents within seven antimicrobial classes (including penicillins, macrolides, fluoroquinolones, and tetracyclines) accounted for 94% of total outpatient prescriptions. Antimicrobial resistance surveillance is particularly necessary in the Midwest region of the United States, as an average of 897 outpatient prescriptions per 1000 persons was issued in this 12-state region in 2011, second only to the southern United States (931 prescriptions per 1000 persons).²⁹ Analyzing local patterns of resistance by geographic region, patient population, and practitioner specialty could provide insight into antimicrobial resistance beyond that relative to inpatient

Table 3. MIC₅₀, MIC₉₀, and percent susceptibility (%S) of Wisconsin *Staphylococcus aureus* isolates to telavancin (TEL), dalbavancin (DAL), and ceftaroline (TAR), stratified by geographic region, 2018

TEL	Northwest	Northcentral	Northeast	Southwest	Southcentral	Lake Winnebago	Southeast	Wisconsin
n	45	43	45	45	44	44	43	309
MIC ₅₀	0.06	0.12	0.06	0.06	0.06	0.06	0.12	0.06
MIC ₉₀	0.12	0.12	0.12	0.06	0.12	0.12	0.12	0.12
%S	100	100	100	100	97.7	100	100	99.7

DAL	Northwest	Northcentral	Northeast	Southwest	Southcentral	Lake Winnebago	Southeast	Wisconsin
n	45	43	45	45	44	44	43	309
MIC ₅₀	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
MIC ₉₀	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
%S	100	100	100	100	100	100	100	100

TAR	Northwest	Northcentral	Northeast	Southwest	Southcentral	Lake Winnebago	Southeast	Wisconsin
n	45	43	45	45	44	44	43	309
MIC ₅₀	0.25	≤ 0.12	0.25	0.25	0.25	0.25	0.25	0.25
MIC ₉₀	0.5	0.25	0.25	0.5	0.5	0.5	0.5	0.5
%S	100	100	100	100	97.7	100	100	99.7

populations or healthcare-associated infections. The SWOTARE program, with its inherent design allowing for participation by rural healthcare facilities, can assist in future analyses.

In this study, three agents with recently established CLSI guidelines^{20,30,31} were tested against each *S. aureus* isolate to contribute to the baseline antibiogram (Table 3). Telavancin does not currently possess a resistant interpretive breakpoint;²⁰ however, one isolate was found to be non-susceptible to this agent (surgical tissue isolate from Southcentral region, MIC of 0.25 µg/mL). MIC₅₀ and MIC₉₀ values were consistent throughout Wisconsin for dalbavancin (both 0.06 µg/mL). *S. aureus* susceptibility to telavancin and ceftaroline demonstrated some variation with respect to MIC values; however, none exceeded the CLSI susceptible breakpoint. Telavancin MIC₅₀ and MIC₉₀ values were calculated at either 0.06 µg/mL or 0.12 µg/mL on a geographic basis. Ceftaroline MIC₅₀ and MIC₉₀ values ranged from ≤ 0.12 µg/mL to 0.5 µg/mL across the state; > 95% of all isolates tested susceptible to these three agents in each region. One daptomycin non-susceptible isolate (MIC of 2 µg/mL) was identified from the Southwest region of the state.

Demographic Variation *S. aureus* Resistance in Wisconsin

In addition to geographic variability associated with MRSA in Wisconsin, we also observed differences as a function of patient age. Patients aged 20–39 years generated the highest proportion of *S. aureus* isolates with a MRSA phenotype (57.4%; Table 4), while MRSA rates in patients aged 0–19 years, 40–59 years, and 60–79 years approximated 30% ($P \leq 0.03$). These findings extend those derived from a United States tertiary care center in which MRSA was detected more

frequently in patients under the age of 24 when compared to other age groups.³²

These authors hypothesized that increased risk of MRSA among younger individuals may be related to increased participation in what was termed risky activity (such as team sports). One past study³³ reported the median age of community-acquired MRSA infection to be significantly less than that in cases of healthcare-associated MRSA infection. Our findings contrast a European study that reported an increased proportion of MRSA in elderly patients when compared to younger patients.³⁴ Further investigation may be warranted in subsequent SWOTARE collections to elucidate a role for patient age in terms of risk for MRSA infection in Wisconsin.

Other differences were noted with levofloxacin and clindamycin. An increased proportion of levofloxacin-resistant *S. aureus* from patients aged 80 or older was observed compared to patients aged 0–19 or 40–59 years ($P \leq 0.046$; Table 4). This elderly population also exhibited an increased percentage of *S. aureus* resistant to clindamycin (36.3%) when compared to 20–39 year olds (16.7%, $P = 0.026$). Moreover, when compared to the 40–59 year-old population, resistance rates trended higher in the 80+ years group ($P = 0.08$). These data extend findings from David, et al³⁵ who demonstrated increased *S. aureus* resistance to clindamycin in elderly patients when compared to pediatric patients. Moreover, findings from pediatric patients treated in United States military facilities from 2005–2014 documented annual clindamycin resistance rates between 9.3% and 14.4%.³⁶ However, recent pediatric data from the Baltimore, Maryland area collected over a 12-year interval reported an

Table 4. Comparative Wisconsin *Staphylococcus aureus* resistance to cefoxitin (FOX), levofloxacin (LEV), erythromycin (ERY), clindamycin (CLI), doxycycline (DOX), and trimethoprim-sulfamethoxazole (T/S), stratified by age group, 2018

Age group	Percentage Resistant to Antimicrobial Agents					
	FOX	LEV	ERY	CLI	DOX ^a	T/S
0-19	35.0	15.0	55.0	20.0	2.5	0.0
20-39	57.4 ^b	24.1	51.9	16.7	1.9	1.9
40-59	30.7	21.0	43.6	21.0	4.8	1.6
60-79	30.3	28.4	42.7	28.4	5.5	1.8
80+	40.9	38.6 ^c	56.8	36.3 ^d	4.6	0.0

^aPercentages reflect doxycycline intermediate resistance (MIC 8 µg/mL); isolates with MIC ≥ 16 µg/mL were not observed.

^bP ≤ 0.03 vs. 0-19 years, 40-59 years, 60-79 years

^cP ≤ 0.046 vs 40-59 years, 0-19 years

^dP = 0.026 vs. 20-39 years

increase in clindamycin resistance rate from 21% to 38% in MRSA clinical isolates and from 5% to 40% in MSSA isolates.³⁷ Sutter et al.³⁶ also noted significant decreases in MSSA susceptibility to clindamycin over time when compared to pediatric MRSA isolates. As such, revisiting these demographic studies in subsequent Wisconsin surveillance efforts may be warranted. In the context of additional alternative staphylococcal regimens, trimethoprim-sulfamethoxazole resistance rates and distributions of doxycycline intermediate MIC values did not demonstrate variation across age groupings ($P \geq 0.36$ and $P \geq 0.28$, respectively; Table 4).

No significant differences were noted with respect to cefoxitin, levofloxacin, erythromycin, and clindamycin resistance rates in isolates of *S. aureus* when stratified by inpatient, outpatient, or emergency department encounter. Resistance rates ranged from 32.8% to 41.0% between the three facility groupings for cefoxitin ($P \geq 0.18$), 21.4% to 30.3% for levofloxacin ($P \geq 0.10$), 46.7% to 50.0% for erythromycin ($P \geq 0.68$), and 17.9% to 27.9% for clindamycin ($P \geq 0.15$). These data further suggest that potential outpatient bias factored little into observations made in the study.

Limitations

Limitations to the desired two rural laboratory/one larger-population center laboratory approach to study site recruitment included regions with fewer hospital microbiology laboratories and regions with increased population density. The Southeast, Northeast, and Lake Winnebago regions were represented by fewer than two rural laboratories. The Northeast region of Wisconsin has experienced a movement toward hospital microbiology laboratory consolidation over the past decade. With respect to the Lake Winnebago and Southeast regions, population density figures of 151.4 and 670.8 inhabitants/square mile were calculated, respectively. In contrast, three of the Wisconsin regions exhibited population density data of < 50 inhabitants/square mile. As further evidence of measures taken to ensure a representative sampling that was not biased

toward heavily urban centers during this 2018 surveillance effort, 38% of participating hospital microbiology laboratories were derived from municipalities with populations < 15,000 (per 2010 United States census data), with an aggregate 58% of participants derived from municipalities with populations < 35,000.

A second limitation is related to potential *S. aureus* clonality contributing to noted geographic variation. We were unable to investigate this possibility during this initial surveillance effort. As mentioned previously, approximately one-half of isolates were derived from hospital laboratories in rural areas of the state; these laboratories do not have the capacity to perform molecular epidemiologic studies. In addition, the limited demographic information requested of the study sites did not inquire about potential mini-outbreak status of isolates. Moreover, limited demographic information (as allowed by Institutional Review Board) did not allow for provision of patient identifiers, as such, retrospective investigation of potential mini-outbreak status could not be facilitated.

Conclusion

While limited to an extent by numbers of isolates collected in the initial year of SWOTARE *S. aureus* surveillance, presented data identified both geographic and demographic-based differences in antimicrobial resistance among Wisconsin *S. aureus* isolates. By carefully analyzing regional data, trends can be realized that are not apparent at a national level. In addition, regions of the state that warrant increased vigilance and intervention can be identified in efforts to mitigate antimicrobial resistance. Continued future surveillance efforts may reveal additional trends and contribute to stewardship and intervention opportunities at the local level.

Acknowledgments

The authors are grateful to the following individuals for collection of isolates throughout 2018:

Sonja Alt, Monroe
 Jorn Bansberg, Viroqua
 Sherry Barta, Green Bay
 Eric Beck, PhD, West Allis
 Tim Block, West Bend
 Becky Brooks, Stevens Point
 Tracy Felland, Janesville
 Thomas Fritsche, MD, PhD, Marshfield
 Ben Kaetterhenry, Appleton
 Debra Kieler, Platteville
 Timothy Kramme, Milwaukee
 Joshua Kropp, Weston
 Kathy Lang, Ashland
 Debbie Maedke, Manitowoc
 Brooke Olson, Marshfield
 Mattie Pitts, Spooner
 Ray Podzorski, PhD, Madison
 Lori Reed, Amery
 Andrea Roder, Green Bay
 Karen Siebers, Neenah
 Brian Simmons, Prairie du Chien
 Mary A. Smith, St. Croix Falls
 Frances Spray-Larson, PhD, Fort Atkinson
 Janelle Stearns, Eau Claire
 Sarah Stoner, La Crosse
 Ellen Wirtz, Fond du Lac

References

- World Health Organization. Antibiotic Resistance. 2018. Available at: www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. Accessed April 18, 2019.
- Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol*. 2013;34(1):1-14.
- Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. *N Engl J Med*. 2018;379(18):1732-1744.
- Thomson KS. The immaculate carbapenemase study. *J Clin Microbiol*. 2017;55(6):1608-1611.
- Lamoth F, Kontoyiannis DP. The *Candida auris* alert: facts and perspectives. *J Infect Dis*. 2018;217(4):516-520.
- Day MJ, Spiteri G, Jacobsson S, et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in *Neisseria gonorrhoeae* in 25 European countries, 2016. *BMC Infect Dis*. 2018;18(1):609.
- Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clin Infect Dis*. 2009;49(8):1175-1184.
- World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. Available at: www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed March 20, 2019.
- Munson E. Biographical feature: Clyde Thornsberry, Ph.D. *J Clin Microbiol*. 2016;54(2):250-253.
- Lowy FD. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest*. 2003;111(9):1265-1273.
- World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. Available at: <https://www.who.int/drugresistance/documents/surveillance-report/en/>. Accessed April 25, 2019.
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. Available at: <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>. Accessed April 18, 2019.
- Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among *Staphylococcus aureus* from the SENTRY antimicrobial surveillance program. *Open Forum Infect Dis*. 2019;6(Suppl 1):S47-S53.
- Sader HS, Mendes RE, Streit JM, Flamm RK. Antimicrobial susceptibility trends among *Staphylococcus aureus* isolates from U.S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program, 2010-2016. *Antimicrob Agents Chemother*. 2017;61(9):e01043-17.
- Landrum ML, Neumann C, Cook C, et al. Epidemiology of *Staphylococcus aureus* blood and skin and soft tissue infections in the US military health system, 2005-2010. *JAMA*. 2012;308(1):50-59.
- Munson E, Zeman H, Hueppchen E. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): epidemiologic correlates for 2016 surveillance isolates. *Gundersen Medical Journal*. 2017;10(1):41-48.
- Munson E, Hueppchen E, Zeman H. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): introduction to the program and summary of 2016 geographic variation. *WMJ*. 2018;117(3):116-121.
- Zeman H, Martin R, Munson E, Schulte R. Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): summary of 2017 findings with focus on changing resistance patterns in selected antimicrobial classes. *Gundersen Medical Journal*. In press.
- Munson E, Block TK, Bowles EJ, et al. Surveillance of Wisconsin antibacterial susceptibility patterns. *WMJ*. 2016;115(1):29-36.
- Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, M100. 28th informational supplement. Wayne, PA: CLSI; 2018.
- Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M07. 10th ed. Wayne, PA: CLSI; 2015.
- McKinney TK, Sharma VK, Craig WA, Archer GL. Transcription of the gene mediating methicillin resistance in *Staphylococcus aureus* (*mecA*) is corepressed but not coincided by cognate *mecA* and beta-lactamase regulators. *J Bacteriol*. 2001;183(23):6862-6868.
- Prabhu K, Rao S, Rao V. Inducible clindamycin resistance in *Staphylococcus aureus* isolated from clinical samples. *J Lab Physicians*. 2011;3(1):25-27.
- Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci. *J Clin Microbiol*. 2003;41(10):4740-4744.
- Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States: five-year results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. *JAMA Ophthalmol*. 2015;133(12):1445-1454.

26. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52(3):e18-e55.
27. McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of resistance among USA300 methicillin-resistant *Staphylococcus aureus* isolates causing invasive disease in the United States. *Antimicrob Agents Chemother*. 2010;54(9):3804-3811.
28. Jones RN, Stilwell MG, Wilson ML, Mendes RE. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. *Diagn Microbiol Infect Dis*. 2013;76(1):69-72.
29. Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. *Clin Infect Dis*. 2015;60(9):1308-1316.
30. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, M100. 23rd informational supplement. Wayne, PA: CLSI; 2013.
31. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, M100. 26th informational supplement. Wayne, PA: CLSI; 2016.
32. Jacobus CH, Lindsell CJ, Leach SD, Fermann GJ, Kressel AB, Rue LE. Prevalence and demographics of methicillin resistant *Staphylococcus aureus* in culturable skin and soft tissue infections in an urban emergency department. *BMC Emerg Med*. 2007;7(1):19.
33. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant *Staphylococcus aureus* infection. *JAMA*. 2003;290(22):2976-2984.
34. Pomorska-Wesołowska M, Różańska A, Natkaniec J, et al. Longevity and gender as the risk factors of methicillin-resistant *Staphylococcus aureus* infections in southern Poland. *BMC Geriatr*. 2017;17(1):51.
35. David MZ, Crawford SE, Boyle-Vavra S, Hostetler MA, Kim DC, Daum RS. Contrasting pediatric and adult methicillin-resistant *Staphylococcus aureus* isolates. *Emerg Infect Dis*. 2006;12(4):631-637.
36. Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing susceptibility of *Staphylococcus aureus* in a US pediatric population. *Pediatrics*. 2016;137(4):e20153099.
37. Khamash DF, Voskertchian A, Tamma PD, Akinboyo IC, Carroll KC, Milstone AM. Increasing clindamycin and trimethoprim-sulfamethoxazole resistance in pediatric *Staphylococcus aureus* infections. *J Pediatric Infect Dis Soc*. 2019;8(4):351-353.

Author Affiliations

Rebecca H. Schulte, BS* and Erik Munson, PhD*†

*College of Health Sciences, Marquette University,
Milwaukee, Wisconsin USA

†Wisconsin Clinical Laboratory Network Technical Advisory
Group, Madison, Wisconsin USA